Nature 316, 826 - 828 (29 August 1985); doi:10.1038/316826a0

Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia

Michelle M. Le Beau, Carol A. Westbrook, Manuel O. Diaz, Janet D. Rowley & Moshe Oren^*

Joint Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
^*Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel

Recent studies have demonstrated that the cellular tumour antigen p53 (ref. 1) can complement activated ras genes in the transformation of rat fibroblasts, suggesting that the gene encoding p53 may act as an oncogene^2,3. Here, by using in situ chromosomal hybridization^4,5, we have mapped the p53 gene to human chromosome 17, at bands 17q21−q22, the region containing one of the breakpoints in the translocation t(15;17) (q22;q21) associated with acute promyelocytic leukaemia (APL)^6,7. Hybridization of p53 and erb-A (17qll-ql2) probes to malignant cells from three APL patients indicated that the p53 gene is translocated to chromosome 15 (15q+), whereas erb-A remains on chromosome 17. Analysis of variant translocations demonstrates that the 15q+ chromosome contains the conserved junction⁸, suggesting a role for p53 in the pathogenesis of APL. However, rearrangements of the p53 gene were not detected on Southern blotting of DNA from leukaemic cells of four APL patients with t(15;17).

References

1.	Klein, G. (ed.) Advances in Viral Oncology Vol. 2 (Raven, New York, 1982).
2.	Eliyahu, D., Raz, A., Gruss, P., Givol, D. & Oren, M. Nature 312, 646−649 (1984).
3.	Parada, L. F., Land, H., Weinberg, R. A., Wolf, D. & Rotter, V. Nature 312, 649−651 (1984).
4.	Harper, M. E. & Saunders, G. F. Chromosoma 83, 431−439 (1981).
5.	Le Beau, M. M., Westbrook, C. A., Diaz, M. O. & Rowley, J. D. Nature 312, 70−71 (1984).
6.	Rowley, J. D. et al. Int. J. Cancer 20, 869−872 (1977).
7.	Larson, R. A. et al. Am. J. Med. 76, 827−841 (1984).
8.	Rowley, J. D. Science 216, 749−751 (1982).
9.	Zakut-Houri, R. et al. Nature 306, 594−597 (1983).
10.	Mitelman, F. Cytogenet. Cell Genet. 36, 1−516 (1983).
11.	Dayton, A. I. et al. Proc. natn. Acad. Sci. U.S.A. 81, 4495−4499 (1984).
12.	Sheer, D. et al. Proc. natn. Acad. Sci. U.S.A. 80, 5007−5011 (1983).
13.	Sheer, D. et al. Ann. hum. Genet. (in the press).
14.	Matlashewski, G. et al. EMBO J. 3, 3257−3262 (1984).
15.	Wolf, D. & Rotter, V. Proc. natn. Acad. Sci. U.S.A. 82, 790−794 (1984).
16.	Heisterkamp, N. et al. Nature 306, 239−242 (1983).
17.	Croce, C. M. et al. Proc. natn. Acad. Sci. U.S.A. 80, 6922−6926 (1983).
18.	Erikson, J. et al. Proc. natn. Acad. Sci. U.S.A. 80, 7581−7585 (1983).
19.	Groffen, J. et al. Cell 36, 93−99 (1984).
20.	Bernstein, R., Mendelow, B., Morcom, G. & Bezwoda, W. Br. J. Haemal. 46, 311−314 (1980).
21.	Ohyashiki, K. et al. Cancer Genet. Cytogenet. 14, 247−255 (1985).
22.	Yamada, K. et al. Cancer Genet. Cytogenet. 9, 93−99 (1983).
23.	Van den Berghe, H. et al. Cancer 43, 558−562 (1979).